- Diabetes, Obesity and Metabolism
- Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
-
Adie Viljoen, Stephen C. Bain
-
Endocrinol Metab. 2023;38(1):25-33. Published online February 6, 2023
-
DOI: https://doi.org/10.3803/EnM.2022.1642
-
-
4,110
View
-
354
Download
-
6
Web of Science
-
6
Crossref
-
Abstract
PDFPubReader ePub
- The therapeutic benefits of the incretin hormone, glucagon-like peptide 1 (GLP1), for people with type 2 diabetes and/or obesity, are now firmly established. The evidence-base arising from head-to-head comparative effectiveness studies in people with type 2 diabetes, as well as the recommendations by professional guidelines suggest that GLP1 receptor agonists should replace more traditional treatment options such as sulfonylureas and dipeptidyl-peptidase 4 (DPP4) inhibitors. Furthermore, their benefits in reducing cardiovascular events in people with type 2 diabetes beyond improvements in glycaemic control has led to numerous clinical trials seeking to translate this benefit beyond type 2 diabetes. Following early trial results their therapeutic benefit is currently being tested in other conditions including fatty liver disease, kidney disease, and Alzheimer’s disease.
-
Citations
Citations to this article as recorded by
- The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update
Agnieszka Jakubowska, Carel W. le Roux, Adie Viljoen Endocrinology and Metabolism.2024; 39(1): 12. CrossRef - The Association of Circulating Glucagon-Like Peptide-1 with Cognitive Functions and Biomarkers in Alzheimer’s Disease
Mengqing Liu, Nenghong Ma, Xiao Yang, Miao Sun, Xiaowen Li, Yuhui Liu, Qing Chang, Changchun Hei, Jian-Hong Wang Journal of Alzheimer's Disease.2024; 99(2): 525. CrossRef - Energy balance and obesity: the emerging role of glucagon like peptide-1 receptor agonists
Noémie Beauregard, Kurt McInnis, Gary S. Goldfield, Éric Doucet Current Opinion in Clinical Nutrition & Metabolic Care.2024; 27(6): 472. CrossRef - Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
John R. Ussher, Daniel J. Drucker Nature Reviews Cardiology.2023; 20(7): 463. CrossRef - A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena
Stephen C Bain, Thinzar Min The Lancet.2023; 402(10401): 504. CrossRef - Flattening the biological age curve by improving metabolic health: to taurine or not to taurine, that’ s the question
Kwok M. Ho, Anna Lee, William Wu, Matthew T.V. Chan, Lowell Ling, Jeffrey Lipman, Jason Roberts, Edward Litton, Gavin M. Joynt, Martin Wong Journal of Geriatric Cardiology.2023; 20(11): 813. CrossRef
|